Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 20/20 | 0.78 |
| ▸ | EDNRB | P24530 | 13/20 | 0.78 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.78 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | DHPS | P49366 | 1/20 | 0.78 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.78 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3105024 | 0.94 | EDNRA (0.82) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL914924 | 0.93 | EDNRA (0.75) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL617288 | 0.93 | EDNRA (0.72) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL29770411 | 0.93 | EDNRA (0.72) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL625550 | 0.92 | EDNRA (0.71) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL5686011 | 0.92 | EDNRA (0.71) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL12238206 | 0.92 | EDNRA (0.71) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7795452 | 0.92 | EDNRA (0.93) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7947350 | 0.91 | EDNRA (0.83) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL2313655 | 0.89 | EDNRA (0.81) | EDNRAEDNRBABCC3ABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263623-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CADILA HEALTHCARE LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
| US-20110263623-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CADILA HEALTHCARE LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
| EP-2331513-A1 | PROCESS FOR PREPARATION OF BOSENTAN | Cadila Healthcare Limited (IN) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010032261-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CADILA HEALTHCARE LIMITED (IN) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010032261-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CADILA HEALTHCARE LIMITED (IN) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263623-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CYP2D6, CYP3A5, QDPR | EDNRA 146/4885EDNRB 13/4885ABCC3 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.